趋化因子配体18在乳腺癌组织中的表达与预后分析

CCL18 expression and its association with prognosis in breast cancer

目的探讨趋化因子配体18在乳腺癌组织中的表达及其与乳腺癌患者预后的关系。方法入组病例的疾病诊断均以我院病理诊断为准并且均为女性患者,其中共有94例乳腺癌患者的组织标本,47例良性乳腺疾病患者的组织标本,对照组组织标本为良性乳腺病病灶周边的正常乳腺组织,共27例。采用免疫组化Envision方法,对标本检测CCL18、ER、PR、Her-2以及Ki-67等的表达。并对乳腺癌患者进行随访。结果在对照组、良性乳腺病组均未发现CCL18表达,在乳腺癌患者组中,CCL18的阳性表达率为67.02%(63/94);乳腺癌组CCL18的阳性表达率较对照组及良性乳腺疾病组显著升高(P<0.05)。在表达CCL18的63例乳腺癌患者中,CCL18的表达水平与肿瘤大小、淋巴结转移数目、临床分期,乳腺癌的分子类型以及ER、PR、Her-2的表达均有密切联系(P<0.05)。CCL18阳性乳腺癌患者的无病生存期(DFS)、总生存期(OS)均较CCL18阴性的乳腺癌患者的差(P<0.05)。结论 CCL18与乳腺癌的生物学特性密切相关,乳腺癌的一个重要的生物学指标,并且与乳腺患者的预后密切相关,可作为判断乳腺癌预后的一个重要参考指标进行研究。

Objective To research the expression of CCL18 in breast cancer and its association with prognosis of breast cancer. Methods Ninety-four tissue samples from patients with breast cancer were collected,and 47 tissue samples with benign breast diseases were also collected. The control group contained 27 samples,which were collected from tissues aside the benign breast disease leisions.All of the cases were female..Envision immunohistochemical method was used to examine CL18, ER, PR, Her-2 and Ki67. All of the patients with breast cancer were followed-up for a mean of 39 months. Results Among patients with benign breast diseases and the control group, CCL18 was not found..While in the 94 patients with breast cancer,CCL18 was found in 63 cases, positive ratio was 67.02%,and CCL18 was significantly up-regulated in breast cancer samples as compared with benign tumors or normal breast tissues（P〈0.05）.Moreover,the expression level of CCL18 was different according to the size of tumors,the number of metastasized lymph node,tumor stage,subtype of breast cancer, ER, PR, Her-2, and all of the differences were significant（P〈0.05）. High CCL18 expression was associated with poor disease-free survival and overall survival（both P〈0.05）.Conclusion CCL18 showed high expression in breast cancer,wirch was associated with poor prognosis and may serve as an independent prognostic marker for investigating breast cancer.